Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 9-fluoro-10-(n-(4'-methyl)piperazinyl)-7-oxo-2,3-dihydro-7h-pyrido(1,2,3de)-1,4-benzothiazine-6-carboxylic Acid
2. Mf 934
3. Mf-934
4. Rufloxacin Hydrobromide
5. Rufloxacin Hydrochloride
6. Rufloxacin Monohydrobromide
7. Rufloxacin Monohydrochloride
1. 101363-10-4
2. Mf 934
3. Nsc-759835
4. Chebi:8909
5. Rufloxacin (inn)
6. Y521xm2900
7. 7h-pyrido[1,2,3-de]-1,4-benzothiazine-6-carboxylic Acid, 9-fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo-
8. Rufloxacine
9. Rufloxacino
10. Rufloxacinum
11. Rufloxacin [inn]
12. 9-fluoro-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7h-[1,4]thiazino[2,3,4-ij]quinoline-6-carboxylic Acid
13. 9-fluoro-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7h-[1,4]thiazino[2,3,4-ij]quinoline-6-carboxylic Acid;9-fluoro-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7h-[1,4]thiazino[2,3,4-ij]quinoline-6-carboxylic Acid
14. Smr000466373
15. Rufloxacine [french]
16. Rufloxacinum [latin]
17. Rufloxacino [spanish]
18. Rufloxacin [inn:ban]
19. Sr-01000612324
20. Ncgc00074024-02
21. Unii-y521xm2900
22. Rufloxacin [mi]
23. Rufloxacin [who-dd]
24. Mls000759502
25. Mls001424127
26. Schembl135502
27. Chembl295619
28. Dtxsid6048412
29. Hms2051k22
30. Hms2090n07
31. Hms3264m18
32. Hms3393k22
33. Hms3715p09
34. Pharmakon1600-01502335
35. Zinc538328
36. Hy-b0902
37. Rkl10066
38. Bbl008945
39. Nsc759835
40. Stk711124
41. Akos004120047
42. Ccg-100908
43. Cs-4367
44. Db13772
45. Nc00158
46. Nsc 759835
47. As-79943
48. Ft-0631011
49. D02474
50. Ab00474020-18
51. Ab00474020-20
52. Ab00474020_21
53. 363r104
54. Q3942356
55. Sr-01000612324-5
56. Sr-01000612324-6
57. 7-fluoro-6-(4-methylpiperazin-1-yl)-10-oxo-4-thia-1-azatricyclo[7.3.1.0^{5,13]trideca-5(13),6,8,11-tetraene-11-carboxylic Acid
58. 7-fluoro-6-(4-methylpiperazin-1-yl)-10-oxo-4-thia-1-azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic Acid
59. 8-fluoro-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6h-1-thia-3a-aza-phenalene-5-carboxylic Acid
60. 8-fluoro-9-(4-methylpiperazin-1-yl)-6-oxo-2,3-dihydro-6h-1-thia-3a-aza-phenalene-5-carboxylic Acid
61. 9-fluoro-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2h-[1,4]thiazino[2,3,4-ij]quinoline-6-carboxylic Acid
62. 9-fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(1,2,3-de)-1,4-benzothiazine-6-carboxylic Acid
63. 9-fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic Acid
| Molecular Weight | 363.4 g/mol |
|---|---|
| Molecular Formula | C17H18FN3O3S |
| XLogP3 | -0.3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 2 |
| Exact Mass | 363.10529078 g/mol |
| Monoisotopic Mass | 363.10529078 g/mol |
| Topological Polar Surface Area | 89.4 Ų |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 608 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Topoisomerase II Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01M - Quinolone antibacterials
J01MA - Fluoroquinolones
J01MA10 - Rufloxacin
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
ABOUT THIS PAGE
A Rufloxacin Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rufloxacin Hydrochloride, including repackagers and relabelers. The FDA regulates Rufloxacin Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rufloxacin Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Rufloxacin Hydrochloride supplier is an individual or a company that provides Rufloxacin Hydrochloride active pharmaceutical ingredient (API) or Rufloxacin Hydrochloride finished formulations upon request. The Rufloxacin Hydrochloride suppliers may include Rufloxacin Hydrochloride API manufacturers, exporters, distributors and traders.
Rufloxacin Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rufloxacin Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Rufloxacin Hydrochloride GMP manufacturer or Rufloxacin Hydrochloride GMP API supplier for your needs.
A Rufloxacin Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Rufloxacin Hydrochloride's compliance with Rufloxacin Hydrochloride specifications and serves as a tool for batch-level quality control.
Rufloxacin Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Rufloxacin Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rufloxacin Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Rufloxacin Hydrochloride EP), Rufloxacin Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rufloxacin Hydrochloride USP).
LOOKING FOR A SUPPLIER?
